U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935356) titled 'A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia' on Nov. 09.
Brief Summary: Glanzmann thrombasthenia (GT) is a serious inherited bleeding disorder. In GT, platelets, the blood cells that normally stick together at the site of an injury to stop bleeding, are unable to properly do so. As a result, bleeding does not stop as it should. Bleeding in GT often starts without warning, can happen frequently, and can be severe. It most commonly affects the nose, mouth and gums, gastrointestinal tract, and skin, and many women and girls with GT experience heavy menstrual bleeding. Over time, bleeding can lead to iron deficiency an...